Nickel hypersensitivity was confirmed with skin patch testing. The microinserts were removed hysteroscopically, and the patient improved.
CONCLUSION:
If a patient experiences symptoms of an allergic reaction after hysteroscopic sterilization, referral to an allergy specialist is recommended. If nickel hypersensitivity is confirmed, the microinserts should be removed; this may be performed under hysteroscopic guidance. (Obstet Gynecol 2011; 117: 461-2) DOI: 10.1097/AOG.0b013e3181f73021″
“Castor oil methyl ester (COME) was produced by reactive extraction of castor seed and the purpose of this study is to investigate the feasibility of the reaction and to find out optimum reaction conditions. Reactive extraction of castor seed was carried out at varied reaction conditions such JNJ-26481585 ic50 as oil to methanol molar ratio (1:50-1:250), catalyst concentration (0.5-2%), temperature
(35-65 degrees C) and rate of mixing (200-800 rpm) and the effect of above parameters on reactive extraction were investigated. The optimum reaction conditions for reactive extraction were found to be 1% KOH (wt basis of oil), reaction temperature SCH727965 nmr 65 degrees C, reaction time 3 h, methanol to oil molar ratio 250:1 and mixing speed of 600 rpm. The kinetics of the reaction was studied and the activation energy was found to be 38.916 kJ mol(-1). The potential use of COME as bio lubricants is promising due to its high viscosity, low pour point, and good lubricity. Economic analysis and sensitivity study of reactive extraction has been carried out which estimated the price of COME at $3.71/gal. (C) 2012 Elsevier
B.V. All rights reserved.”
“Previous research has shown that FXYD6 (FXYD domain-containing ion transport regulator 6) is highly increased in bile duct tumor. However, the biological function of FXYD6 is unclear. We aim to prepare LOXO-101 and identify a monoclonal antibody against FXYD6, which will be used in diagnostics and as a tool in understanding the role of FXYD6 in pathogenesis of hepatobiliary cancer. In this study, hybridoma cell fusion technology is used for production of FXYD6 monoclonal antibody. BALB/c mice are immunized with FXYD6 synthetic peptide fragment. Hybridoma clones are screened using indirect enzyme-linked immunosorbent assay (ELISA). FXYD6 monoclonal antibody is produced by ascites revulsion. Protein A affinity chromatography is used for the purification of FXYD6 monoclonal antibody. Titer and specificity of monoclonal antibody are assessed by ELISA. Expression of FXYD6 in pancreatic cancer is detected by immunohistochemistry. As a result, one stable hybridoma cell clone producing FXYD6 monoclonal antibody has been established. 2.86mg monoclonal antibody against FXYD6 with high specificity is prepared with titer of 1:5400. Immunohistochemistry shows that FXYD6 positive staining occurs in the cell membrane of pancreatic cancer, which results in an advantage in investigating the tissue distribution and biological function of FXYD6.